Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors.

Jian Jenny ChenMelanie Y VincentDale ShepardDavid PeereboomDevalingam MahalingamJames BattisteManish R PatelDejan JuricPatrick Y WenAndrea J BullockJennifer Eva SelfridgeShubham PantJoyce LiuWendy LiSusanne FyfeSuming WangVictor ZotaJames MahoneyRandolph S WatnickMichael CieslewiczJing Watnick

Published in: Communications medicine (2024)

VT1021 is safe and well-tolerated in patients with solid tumors in a phase I expansion study. VT1021 has advanced to a phase II/III clinical study in glioblastoma (NCT03970447).

Keyphrases

phase ii
clinical trial
open label